About caris life sciences inc. - CAI
Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.
CAI At a Glance
Caris Life Sciences, Inc.
750 West John Carpenter Freeway
Irving, Texas 75039
| Phone | 1-866-771-8946 | Revenue | 812.03M | |
| Industry | Biotechnology | Net Income | -68,088,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 96.971% | |
| Fiscal Year-end | 12 / 2026 | Employees | 1,846 | |
| View SEC Filings |
CAI Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 9.387 |
| Price to Book Ratio | 13.204 |
| Price to Cash Flow Ratio | 101.03 |
| Enterprise Value to EBITDA | 107.048 |
| Enterprise Value to Sales | 8.928 |
| Total Debt to Enterprise Value | 0.059 |
CAI Efficiency
| Revenue/Employee | 439,887.866 |
| Income Per Employee | -36,884.074 |
| Receivables Turnover | 7.241 |
| Total Asset Turnover | 1.105 |
CAI Liquidity
| Current Ratio | 7.848 |
| Quick Ratio | 7.347 |
| Cash Ratio | 6.293 |
CAI Profitability
| Gross Margin | 66.397 |
| Operating Margin | 5.556 |
| Pretax Margin | -8.385 |
| Net Margin | -8.385 |
| Return on Assets | -9.267 |
| Return on Equity | -45.374 |
| Return on Total Capital | -6.775 |
| Return on Invested Capital | -12.616 |
CAI Capital Structure
| Total Debt to Total Equity | 74.083 |
| Total Debt to Total Capital | 42.556 |
| Total Debt to Total Assets | 37.994 |
| Long-Term Debt to Equity | 72.952 |
| Long-Term Debt to Total Capital | 41.907 |